From DCAT Value Chain Insights (VCI)
Valeant Pharmaceuticals International has appointed Louis W. Yu, PhD, to the newly created position of chief quality officer, global quality, effective on October 3, 2016. Dr. Yu will report to Joseph C. Papa, chairman and chief executive officer of Valeant. As a new member of Valeant's executive committee, Dr. Yu will oversee all aspects of quality and regulatory compliance for all of Valeant's global businesses and operating sites.
Dr. Yu joins Valeant with more than 30 years of leadership experience in the quality and research and development functions of generic and branded pharmaceutical companies. He was executive vice president, global quality and compliance at The Perrigo Company from November 2006 to January 2016, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments. He also served between May 2016 and September 2016 as the senior vice president, global quality and compliance at AMRI, a contract development and manufacturing organization company.
Source: Valeant Pharmaceuticals International
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription